Literature DB >> 19638319

The changing landscape of cancer drug discovery: a challenge to the medicinal chemist of tomorrow.

Klaus Pors1, Frederick W Goldberg, Christopher P Leamon, Alan C Rigby, Scott A Snyder, Robert A Falconer.   

Abstract

Since the development of the first cytotoxic agents, synthetic organic chemistry has advanced enormously. The synthetic and medicinal chemists of today are at the centre of drug development and are involved in most, if not all, processes of drug discovery. Recent decreases in government funding and reformed educational policies could, however, seriously impact on drug discovery initiatives worldwide. Not only could these changes result in fewer scientific breakthroughs, but they could also negatively affect the training of our next generation of medicinal chemists.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19638319     DOI: 10.1016/j.drudis.2009.07.004

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  1 in total

1.  Exploration of [2 + 2 + 2] cyclotrimerisation methodology to prepare tetrahydroisoquinoline-based compounds with potential aldo-keto reductase 1C3 target affinity.

Authors:  Ana R N Santos; Helen M Sheldrake; Ali I M Ibrahim; Chhanda Charan Danta; Davide Bonanni; Martina Daga; Simonetta Oliaro-Bosso; Donatella Boschi; Marco L Lolli; Klaus Pors
Journal:  Medchemcomm       Date:  2019-06-27       Impact factor: 3.597

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.